Related Experiment Video
Updated: May 2, 2026
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Multi-specific antibodies for cancer immunotherapy
Ron D Jachimowicz1, Sven Borchmann, Achim Rothe
1Department I of Internal Medicine, Innate Immunity Group, University Hospital Cologne, Joseph Stelzmann Str. 9, 50937, Cologne, Germany, ron.jachimowicz@uk-koeln.de.
Abstract:
Targeted treatment of cancer with monoclonal antibodies has added to the beneficial outcome of patients. In an attempt to improve anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research arena. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies, which are the standard first-line therapy in several tumor entities. In this review, we will assess selected multi-specific antibodies in pre-clinical and clinical development that may be new treatment options for cancer patients in the very near future. We will further evaluate therapy modalities including the timely distribution or the combination of various therapeutic approaches and assess the potential role of multi-specific antibodies in cancer treatment.
Insights
Multi-specific antibodies show promise for improving cancer treatment outcomes. This review assesses their potential as novel therapeutic options for patients with various tumor types.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Monoclonal antibodies have improved cancer patient outcomes.
- Multi-specific antibodies are being researched to enhance anti-tumor activity.
- Few multi-specific antibodies have reached advanced clinical trials compared to traditional monoclonal antibodies.
Purpose of the Study:
- To review selected multi-specific antibodies in pre-clinical and clinical development.
- To evaluate therapeutic strategies involving multi-specific antibodies.
- To assess the future role of multi-specific antibodies in cancer treatment.
Main Methods:
- Literature review of pre-clinical and clinical studies on multi-specific antibodies.
- Assessment of clinical trial data for multi-specific antibody constructs.
- Evaluation of therapeutic modalities and combination approaches.
Main Results:
- Selected multi-specific antibodies demonstrate potential as future cancer therapies.
- Further research and clinical trials are needed to establish their efficacy.
- Combination therapies and optimized administration schedules may enhance their effectiveness.
Conclusions:
- Multi-specific antibodies represent a promising advancement in targeted cancer therapy.
- Their clinical development is progressing, with potential to become new treatment options.
- Evaluating optimal therapeutic strategies will be crucial for their successful implementation.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...